[8-K] VINCERX PHARMA INC Reports Material Event

Rhea-AI Filing Summary

Vincerx Pharma, Inc. (Nasdaq: VINC) filed a Form 8-K disclosing multiple events tied to its planned Plan of Liquidation and Dissolution.

Item 1.02 – License Agreement Termination: The October 7, 2020 license agreement with Bayer was terminated effective June 25, 2025. All technology, know-how and IP licensed to Vincerx revert to Bayer.

Item 5.02 – Board Resignations: Six directors - Dr. Ahmed M. Hamdy, Laura I. Bushnell, Dr. Brian J. Druker, Dr. John H. Lee, Francisco D. Salva and Dr. Ruth E. Stevens - resigned effective June 30, 2025, solely due to the pending dissolution. The board size is now one, leaving Acting CEO Dr. Raquel E. Izumi as the sole director.

Item 8.01 – Other Events: A July 7, 2025 press release set July 16, 2025 (10:00 a.m. PT) for the reconvened special stockholder meeting to vote on the dissolution. Management estimates $0.04-$0.08 per share may be available for distribution, cautions that delays would erode this amount through continuing operating costs, and notes potential U.S. federal tax-loss benefits if the plan is approved.

The filing underscores that failure to approve the dissolution could force the company to explore alternatives, including bankruptcy protection. Forward-looking statements highlight uncertainties around timing, operating costs, ultimate distribution amounts, and claim resolutions.

Positive

• Management provided a specific distribution estimate of $0.04-$0.08 per share, offering shareholders clarity on potential recovery.
• Clear timetable for the July 16, 2025 special meeting enables investors to act on the dissolution proposal and related tax planning.

Negative

• Termination of the Bayer license eliminates Vincerx’s core technology and any future operating prospects.
• Six director resignations reduce board oversight to a single member, increasing governance risk.
• Dissolution and liquidation confirm the end of ongoing business operations, with only minimal proceeds expected for shareholders.
• Management warns that delays or failure to approve the plan could exhaust remaining cash and may require seeking bankruptcy protection.

Insights

Equity Research Analyst

TL;DR: Dissolution underway; IP lost, board resigned, shareholders look at $0.04-$0.08 per share.

The termination of the Bayer license severs Vincerx’s principal asset base, confirming there is no viable operating path forward. Six director resignations leave governance concentrated in the acting CEO, a typical step in wind-downs but negative for oversight. Management signals a modest liquidating return of $0.04-$0.08 per share, subject to rapid erosion by ongoing expenses. Investors must weigh these de-minimis proceeds against any current market price. The possibility of bankruptcy if the vote fails elevates downside risk. Overall impact is distinctly negative and material.

Corporate Governance Specialist

TL;DR: Governance collapses to single director; dissolution vote critical.

Resigning a majority of directors during liquidation is standard, yet it concentrates all board authority in one individual, heightening governance risk. The company is transparent about next steps and potential tax benefits, but shareholder influence is now effectively limited to the upcoming vote. Any delay increases cash burn, directly diluting the already thin distribution range. The events are material and negatively skewed for equity holders.

false 0001796129 0001796129 2025-06-30 2025-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2025

Vincerx Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39244		83-3197402
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1825 S. Grant Street San Mateo, California		94402
(Address of principal executive offices)		(Zip Code)

(650) 800-6676

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		VINC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.02 Termination of a Material Definitive Agreement.

Vincerx Pharma, Inc. (the “Company”) and VNRX, Inc., its wholly-owned subsidiary, were parties to that certain License Agreement, dated October 7, 2020, as amended (the “License Agreement”), with Bayer Aktiengesellschaft and Bayer Intellectual Property GmbH (collectively, “Bayer”). As a result of the approval by the Company’s board of directors of the dissolution and liquidation of the Company (the “Dissolution”) and the winding down of its operations, in accordance with the terms of the License Agreement, the License Agreement has been terminated, effective as of June 25, 2025. In connection with such termination, rights to all technology, know-how, and intellectual property licensed to the Company from Bayer under the License Agreement have reverted to Bayer and its licensors.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)  As a result of the pending Dissolution of the Company and the winding down of its operations, Dr. Ahmed M. Hamdy, Laura I. Bushnell, Dr. Brian J. Druker, Dr. John H. Lee, Francisco D. Salva, and Dr. Ruth E. Stevens resigned as members of the Company’s board of directors and all committees thereof effective June 30, 2025. The decision of these directors to resign from the board of directors was due solely to the pending Dissolution of the Company and winding down of its operations and was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices. Following these resignations, the size of the board of directors was reduced to one. Dr. Raquel E. Izumi, the Company’s Acting Chief Executive Officer, is the sole remaining director of the Company.

Item 8.01. Other Events.

On July 7, 2025, the Company issued a press release providing updated information regarding the Special Meeting of Stockholders of the Company, as adjourned, to be held at 10:00 a.m., Pacific time, on July 16, 2025, to consider the proposal to approve the Dissolution pursuant to the Plan of Liquidation and Dissolution (the “Dissolution Proposal”). In this press release, the Company (i) provided an estimated range of between $0.04 to $0.08 per share of its outstanding common stock, based on the Company’s current estimates and assumptions, that could potentially be available for distribution following approval of the Dissolution Proposal to stockholders of record as of the record date for any such distribution, (ii) urged stockholders to vote FOR the Dissolution Proposal, (iii) warned that delays in approving the Dissolution Proposal would result in continued operating costs and expenses, reducing or eliminating any funds available for distribution to stockholders, and (iv) stated that approval of the Dissolution Proposal would help facilitate recognition by U.S. stockholders of any potential tax losses for U.S. federal income tax purposes. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of U.S. federal securities laws. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events and include, but are not limited to, statements about the reasons for approving, and the consequences of failing to approve, the Dissolution; the amounts potentially available for distribution to stockholders; and the potential tax benefits to stockholders of approving the Dissolution Proposal. Forward-looking statements involve risks and uncertainties that may cause actual results or performance to differ materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks involved in dissolving, liquidating, and winding down the Company’s business and affairs; the timing or amount of distributions, if any, to Vincerx’s stockholders, and the accuracy of, and changes to, the assumptions used in estimating such amounts; the Company’s operating costs and expenses, including any unexpected costs, expenses, or claims; the ability to obtain stockholder approval of the Dissolution Proposal and the timeliness of such approval; the risk that the Company may need to seek alternatives to the Dissolution, including seeking protection of the bankruptcy court; and the other factors discussed in the Company’s reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission. All forward-looking statements are based on information available to the Company as of the date of this report. The Company undertakes no duty or obligation to update these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Vincerx Pharma, Inc. issued July 7, 2025.
104		Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 7, 2025

VINCERX PHARMA, INC.
By:		/s/ Raquel E. Izumi
Name:		Raquel E. Izumi
Title:		Acting Chief Executive Officer

FAQ

What distribution per VINC share is estimated in the liquidation?

The company projects approximately $0.04 to $0.08 per outstanding share could be available for distribution.

Why was the Bayer license agreement terminated?

It automatically terminated on June 25, 2025 because Vincerx’s board approved the company’s dissolution; all licensed IP reverts to Bayer.

When is the VINC special stockholder meeting to vote on dissolution?

The adjourned meeting is scheduled for July 16, 2025 at 10:00 a.m. Pacific time.

Who remains on the Vincerx board after the recent resignations?

Only Dr. Raquel E. Izumi, the Acting CEO, remains as the sole director.

What happens if the dissolution proposal is not approved?

Operating costs would continue to reduce available funds and the company may need to consider alternatives, including bankruptcy protection.

Are there potential tax benefits for VINC shareholders if dissolution is approved?

Yes. The company states that approval may help U.S. shareholders recognize potential tax losses for federal income-tax purposes.